Pfizer and BioNTech's COVID-19 vaccine demonstrates over 90% efficacy as hope builds for an early end to the pandem… https://t.co/7oajgLXB0B
US scrambles for resources in COVID-19 response
According to new IHS Markit data, the United States' shortage of medical supplies is being exacerbated by trade disruptions from the COVID-19 epidemic. On a volume basis China accounted for over one-third (34%) of U.S. imports of critical medical supplies in 2019. The medical supply category includes surgical and medical gloves, protective gear and masks, medical and surgical instruments and ventilators.
There is a major risk that the disruptions of the global medical supply chain will hinder the ability to respond effectively to the COVID-19 pandemic, at a time when both the U.S. and global healthcare systems are racing to ensure the capacity needed to combat the virus.
According to the latest annual trade data:
- With $14 billion China is the largest global exporter of medical supplies;
- U.S. annual imports of medical supplies from China stood at $1.1 bn entering 2020, 18% of all medical supplies imports, equating to around 4.8% of the total U.S. medical supply market;
- China is only slightly behind medical supply imports from Mexico which stood at $1.3 billion in 2019;
- Germany is in third place with around $830 million worth of exports to the U.S.
Lack of access to foreign supplies is hindering the U.S. healthcare system's response as demand surges in the face of the COVID-19 pandemic.
So far Mexico has taken few government measures to prevent the spread and appears unprepared compared to other countries. If the epidemic does take hold, it will place further strain on the production and supply for medical goods imported from the United States' southern neighbor.
At the same time, many countries are shutting down their borders on exports of medical supplies and pharmaceutical products to concentrate on the surge in domestic demand as COVID-19 works its way around the world.
The disruption of global trade in medical supplies will be a setback for the global collaboration necessary to deal with a deadly global epidemic.
There's going to be a shortfall in medical supplies, despite the effort by the U.S. and other countries to curtail the impact with a major ramp up in domestic production. Because of the return of Chinese industrial production, and the conversion of many companies away from their traditional businesses to the production of medical supplies, China is becoming the go-to source for other countries in desperate need of supplies.
Learn more and purchase the complete report
- Pfizer and BioNTech's COVID-19 vaccine
- Mixed news on COVID19 vaccines: COVID-19 R&D tracker
- Innovation in Japan’s regenerative sector
- US drug prices could be drastically impacted by Most Favored Nation executive order
- Global healthcare spend to remain stable
- The pandemic pricing dilemma: A COVID-19 vaccine at-cost or for profit?
- US school re-opening decisions in a pandemic environment are complex – data can help
- Trump resurrects International Reference Pricing (IRP) proposal on pharmaceuticals with executive order
Register from the latest on the progression of the pandemic and the future that lies ahead of us from our Vice Pres… https://t.co/GiqhM1V318
We are expecting major clinical readouts from several key COVID-19 vaccine and therapeutics candidates- our weekly… https://t.co/aIcNOmccrx